Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net revenues:
Total net revenues	$ 1,724	$ 916	$ 4,075	$ 2,509
Cost of goods sold	772	384	1,826	1,005
Gross margin	952	532	2,249	1,504
Operating expenses:
Research and development	352	237	993	744
Depreciation and amortization	42	60	123	178
Selling, general and administrative	1,069	753	3,420	2,405
Total operating expenses	1,463	1,050	4,536	3,327
Loss from operations	(511)	(518)	(2,287)	(1,823)
Loss on extinguishment of debt			(199)
Interest expense	(32)	(88)	(146)	(218)
Interest income	1	1	3	3
Other expense	(8)	(27)	(32)	(60)
Net loss	(550)	(632)	(2,661)	(2,098)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(16)		(16)
Net loss attributable to Nephros, Inc.	(566)	(632)	(2,677)	(2,098)
Other comprehensive (loss) income, foreign currency translation adjustments, net of tax	(1)	1	(4)	9
Total comprehensive loss attributable to Nephros, Inc.	$ (567)	$ (631)	$ (2,681)	$ (2,089)
Net loss per common share, basic and diluted	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.04)
Weighted average common shares outstanding, basic and diluted	64,166,988	54,142,791	60,762,239	52,473,518
Product Revenue [Member]
Net revenues:
Total net revenues	$ 1,648	$ 841	$ 3,822	$ 2,316
License, Royalty and Other Revenues [Member]
Net revenues:
Total net revenues	$ 76	$ 75	$ 253	$ 193